Literature DB >> 8938156

Low lipoprotein (a) levels during acute viral hepatitis.

H C Geiss1, M M Ritter, W O Richter, P Schwandt, R Zachoval.   

Abstract

High serum concentrations of lipoprotein (a) [Lp(a)] are considered a risk factor for premature atherosclerosis. Besides apolipoprotein B-100, Lp(a) consists of apolipoprotein (a) [apo(a)], which shows a remarkable size polymorphism. The serum concentration of Lp(a) is considerably influenced by this apo(a) phenotype. Because Lp(a) is synthesized in the liver, we wondered whether and to what extent Lp(a) levels might be affected by acute liver disease. We compared Lp(a) serum concentrations in 74 patients (54% male, 46% female; mean age, 46 years) with acute viral hepatitis (32, 28, and 14 with hepatitis A, B, and C, respectively) with those in 404 healthy controls (57% men, 43% women; mean age, 47 years). In addition, the intraindividual course of Lp(a) concentration during and after acute hepatitis was followed in a subgroup of 23 patients (15, 6, and 2 with hepatitis A, B, and C, respectively). During acute hepatitis, median Lp(a) concentrations in the patient group were significantly diminished compared with controls (7 vs. 17 mg/dL;P < .0001, Mann-Whitney test). Any bias by an unequal isoform distribution was excluded because there was no significant difference in the isoform distribution between patients and controls (P > .10, chi2 test). Furthermore, the decrease in Lp(a) concentration during acute hepatitis was independent of the molecular weight of the apo(a) isoform. Longitudinally observed patients showed a marked increase in Lp(a) concentration during convalescence (7 to 32 mg/dL;P < .0001, Wilcoxon test). Our results show that acute hepatitis is associated with decreased Lp(a) serum levels. Further studies are needed to evaluate whether Lp(a) serum concentration might be clinically useful as a parameter of liver function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938156     DOI: 10.1002/hep.510240602

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Impaired plasma lipid profiles in acute hepatitis.

Authors:  Libo Luo; Xiangke Pu; Yongzhong Wang; Ning Xu
Journal:  Lipids Health Dis       Date:  2010-01-23       Impact factor: 3.876

2.  Hepatitis B virus infection and coronary atherosclerosis: results from a population with relatively high prevalence of hepatitis B virus.

Authors:  De-Yan Tong; Xiao-Hua Wang; Cong-Feng Xu; Ying-Zhen Yang; Si-Dong Xiong
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

3.  Proteomic analysis for developing new biomarkers of hepatocellular carcinoma.

Authors:  Maria Pleguezuelo; Laura M Lopez-Sanchez; Antonio Rodriguez-Ariza; Jose L Montero; Javier Briceno; Ruben Ciria; Jordi Muntane; Manuel de la Mata
Journal:  World J Hepatol       Date:  2010-03-27

Review 4.  Lipids changes in liver cancer.

Authors:  Jing-Ting Jiang; Ning Xu; Xiao-Ying Zhang; Chang-Ping Wu
Journal:  J Zhejiang Univ Sci B       Date:  2007-06       Impact factor: 3.066

Review 5.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 6.  Non-genetic influences on lipoprotein(a) concentrations.

Authors:  Byambaa Enkhmaa; Lars Berglund
Journal:  Atherosclerosis       Date:  2022-05       Impact factor: 6.847

7.  Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases.

Authors:  Jingting Jiang; Xiaoying Zhang; Changping Wu; Xihu Qin; Guanghua Luo; Haifeng Deng; Minyang Lu; Bin Xu; Min Li; Mei Ji; Ning Xu
Journal:  Lipids Health Dis       Date:  2008-07-24       Impact factor: 3.876

Review 8.  Influence of liver cancer on lipid and lipoprotein metabolism.

Authors:  Jingting Jiang; Peter Nilsson-Ehle; Ning Xu
Journal:  Lipids Health Dis       Date:  2006-03-03       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.